MediWound (MDWD) director Nachum Shamir details shares, RSUs and options

Rhea-AI Filing Summary

MediWound Ltd. director Nachum Shamir has filed a Form 3 showing his initial ownership in the company. He directly holds 49,815 ordinary shares and an additional 1,200 ordinary shares underlying restricted stock units granted on March 4, 2026, which vest in full one year after the grant date.

He also holds a series of equity derivatives over MediWound ordinary shares. These include Series A warrants over 16,336 shares at an exercise price of 13.4750 per share expiring on November 28, 2026, and several stock option grants covering 28,571, 11,800, 12,570, 9,200 and 10,000 underlying shares with exercise prices between 11.8850 and 18.5400, expiring between August 17, 2032 and March 4, 2036. The options granted on March 4, 2026 vest 100% on the one-year anniversary of the grant date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SHAMIR NACHUM

(Last) (First) (Middle)

C/O MEDIWOUND LTD.

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	49,815	D
Ordinary shares(1)	1,200	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Warrants	11/28/2022	11/28/2026	Ordinary shares	16,336	$13.475	D
Stock Option (right to buy ordinary shares)	08/17/2023	08/17/2032	Ordinary shares	28,571	$12.495	D
Stock Option (right to buy ordinary shares)	05/31/2024	05/30/2033	Ordinary shares	11,800	$11.885	D
Stock Option (right to buy ordinary shares)	02/26/2025	02/26/2034	Ordinary shares	12,570	$12.729	D
Stock Option (right to buy ordinary shares)	02/11/2026	02/11/2035	Ordinary shares	9,200	$18.54	D
Stock Option (right to buy ordinary shares)	(2)	03/04/2036	Ordinary shares	10,000	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

2. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.

	/s/ Yaron Meyer, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Nachum Shamir’s Form 3 reveal about his MediWound (MDWD) share ownership?

The Form 3 shows Nachum Shamir directly holds 49,815 MediWound ordinary shares, plus 1,200 ordinary shares underlying restricted stock units. These RSUs were granted on March 4, 2026 and vest fully one year after the grant date, adding to his equity-based compensation position.

What derivative securities over MediWound (MDWD) shares does Nachum Shamir hold?

Nachum Shamir holds Series A warrants over 16,336 MediWound ordinary shares at an exercise price of $13.4750, expiring November 28, 2026. He also holds multiple stock option grants over 28,571, 11,800, 12,570, 9,200 and 10,000 underlying shares, each with specified exercise prices and expirations.

When do Nachum Shamir’s MediWound (MDWD) RSUs and recent options vest?

Restricted stock units underlying 1,200 MediWound ordinary shares were granted to Nachum Shamir on March 4, 2026 and vest 100% on the one-year anniversary. Options referenced in the footnote were also granted March 4, 2026 and vest in full on the same one-year schedule, aligning their vesting dates.

What are the key expiration dates of Nachum Shamir’s MediWound (MDWD) options and warrants?

Nachum Shamir’s Series A warrants over 16,336 MediWound shares expire on November 28, 2026. His stock options over various blocks of shares have expirations on August 17, 2032, May 30, 2033, February 26, 2034, February 11, 2035 and March 4, 2036, respectively.

Does Nachum Shamir’s Form 3 for MediWound (MDWD) show any recent share purchases or sales?

The Form 3 lists Nachum Shamir’s existing holdings of MediWound ordinary shares, RSUs, warrants and options as of the reporting date. It does not record open-market purchases or sales; instead, it establishes his baseline ownership position as a director under SEC reporting rules.